Pillar Biosciences, Inc.

Apr 03, 2025

Pillar Biosciences Receives CMS Coverage for FDA Approved oncoReveal® CDx Pan-Cancer Solid tumor IVD Kit

Feb 18, 2025

Pillar Biosciences and Hamilton Company Announce NGS Application Development and Co-Marketing Agreement

Jan 07, 2025

Pillar Biosciences Enters into Strategic Licensing Agreement for MSK's OncoKB(TM) Precision Medicine Knowledgebase

Nov 14, 2024

Pillar Biosciences to Present Impactful Research Data at 2024 Association for Molecular Pathology (AMP) Annual Meeting

Oct 24, 2024

Pillar Biosciences Receives CPT® Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit

Oct 16, 2024

Pillar Biosciences Announces Expansion of NGS Commercial Partnership with Illumina

Sep 10, 2024

Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing

Aug 27, 2024

Pillar Biosciences Launches oncoReveal(TM) Nexus To Help Accelerate the Delivery of Targeted Therapy

Jul 30, 2024

Pillar Biosciences' FDA Approved Solid Tumor NGS Kit oncoReveal(TM) CDx Launched at Molecular Pathology Laboratory Network, Inc.